$1.44
2.13% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US45773H2013
Symbol
INO

Inovio Pharmaceuticals, Inc. Stock price

$1.44
+0.08 5.88% 1M
-0.46 24.21% 6M
-0.39 21.31% YTD
-6.88 82.69% 1Y
-28.08 95.12% 3Y
-174.00 99.18% 5Y
-92.40 98.47% 10Y
-137.76 98.97% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.03 2.13%
ISIN
US45773H2013
Symbol
INO
Industry

Key metrics

Basic
Market capitalization
$73.4m
Enterprise Value
$5.0m
Net debt
positive
Cash
$68.4m
Shares outstanding
36.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
262.1 | 900.5
EV/Sales
17.9 | 43.7
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
60.5%
Return on Equity
-156.6%
ROCE
-176.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$280.0k | $79.8k
EBITDA
$-102.5m | -
EBIT
$-106.0m | $-97.1m
Net Income
$-96.5m | $-75.2m
Free Cash Flow
$-102.7m
Growth (TTM | estimate)
Revenue
-61.1% | -63.7%
EBITDA
12.0% | -
EBIT
10.9% | 13.6%
Net Income
22.8% | 29.9%
Free Cash Flow
11.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-36,211.8% | -
EBIT
-37,430.1%
Net
-34,079.5% | -94,181.6%
Free Cash Flow
-36,277.7%
More
EPS
$-2.5
FCF per Share
$-2.8
Short interest
11.8%
Employees
134
Rev per Employee
$0.0
Show more

Is Inovio Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Inovio Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Inovio Pharmaceuticals, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Inovio Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.28 0.28
61% 61%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
20% 20%
12,661%
- Research and Development Expense 71 71
6% 6%
25,286%
-103 -103
12% 12%
-36,614%
- Depreciation and Amortization 3.45 3.45
44% 44%
1,232%
EBIT (Operating Income) EBIT -106 -106
11% 11%
-37,844%
Net Profit -96 -96
23% 23%
-34,457%

In millions USD.

Don't miss a Thing! We will send you all news about Inovio Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inovio Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
about 23 hours ago
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1 Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year pri...
Neutral
PRNewsWire
8 days ago
PLYMOUTH MEETING, Pa. , Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025.
Neutral
PRNewsWire
about one month ago
PLYMOUTH MEETING, Pa. , July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Sum...
More Inovio Pharmaceuticals, Inc. News

Company Profile

Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jacqueline Shea
Employees 134
Founded 1983
Website www.inovio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today